{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:07:17Z","timestamp":1761901637620,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.msard.2020.102599","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T12:46:33Z","timestamp":1603889193000},"page":"102599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cardiac sarcoidosis requiring ICD placement and immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis"],"prefix":"10.1016","volume":"47","author":[{"given":"Natalie","family":"Erlich-Malona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102599_bib0001","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1177\/1352458518771276","article-title":"Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment","volume":"24","author":"Graf","year":"2018","journal-title":"Multip. Scler. J."},{"key":"10.1016\/j.msard.2020.102599_bib0002","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1177\/1352458518804124","article-title":"Sarcoidosis following alemtuzumab treatment: autoimmunity mediated by T cells and interferon-\u03b3","volume":"24","author":"Pfeuffer","year":"2018","journal-title":"Multip. Scler. J."},{"issue":"9","key":"10.1016\/j.msard.2020.102599_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/1352458515614092","article-title":"Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort","volume":"22","author":"Willis","year":"2016","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2020.102599_bib0003","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1177\/1352458518790391","article-title":"Sarcoidosis following alemtuzumab treatment for multiple sclerosis","volume":"24","author":"Willis","year":"2018","journal-title":"Multip. Scler. J."},{"issue":"13","key":"10.1016\/j.msard.2020.102599_bib0004","first-page":"e272","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.msard.2020.102599_bib0005","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/thx.2010.155762","article-title":"Sarcoidosis complicating treatment with natalizumab for Crohn\u2019s disease","volume":"66","author":"Parisinos","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.msard.2020.102599_bib0006","unstructured":"Korsten P., Sweiss N.J., Baughman R.P., 2021. Sarcoidosis, in: firestein & Kelly's Textbook of Rheumatology, 124, 2088\u20132104."},{"key":"10.1016\/j.msard.2020.102599_bib0007","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-015-0265-8","article-title":"Impaired survival of regulatory T cells in pulmonary sarcoidosis","volume":"16","author":"Broos","year":"2015","journal-title":"Respirat. Res."},{"issue":"2","key":"10.1016\/j.msard.2020.102599_bib0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2020.102599_bib0009","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"Broos","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2020.102599_bib0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2006.06324.x","article-title":"Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia","volume":"135","author":"Rezvany","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.msard.2020.102599_bib0011","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1212\/WNL.0b013e31827b5927","article-title":"Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis","volume":"80","author":"Cossburn","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2020.102599_bib0012","doi-asserted-by":"crossref","first-page":"e9088","DOI":"10.1371\/journal.pone.0009088","article-title":"Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations","volume":"5","author":"Sweiss","year":"2010","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.msard.2020.102599_bib0013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.12178","article-title":"Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro","volume":"141","author":"Havari","year":"2014","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.msard.2020.102599_bib0014","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/imm.12696","article-title":"Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis","volume":"150","author":"von Kutzleben","year":"2017","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.msard.2020.102599_bib0015","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1212\/NXI.0000000000000194","article-title":"Alemtuzumab long-term immunologic effect: treg suppressor function increases up to 24 months","volume":"3","author":"De Mercanti","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"June","key":"10.1016\/j.msard.2020.102599_bib0016","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3389\/fimmu.2019.01204","article-title":"Alemtuzumab in multiple sclerosis: short- and long-term effects of immunodepletion on the peripheral treg compartment","volume":"10","author":"Haas","year":"2019","journal-title":"Front, Immunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:15Z","timestamp":1761900735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820306738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":17,"alternative-id":["S2211034820306738"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102599","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac sarcoidosis requiring ICD placement and immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102599"}}